Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy. Kelonia is a lentiviral ...

Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a transaction valued at more than $2 billion, The Wall Street Journal reported Sunday, citing people familiar with the ...

Eli Lilly said it has agreed to acquire biotech company Kelonia Therapeutics. Lilly will pay $3.25 billion upfront and up to $7 billion in total, the company said. Kelonia is developing technology to ...

April 27 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up ‌to $2.3 billion in cash, as the U.S. drugmaker looks to ...

Investors often mistake share price for valuation. While Eli Lilly's stock price looks expensive on the surface, the company's underlying valuation metrics are quite modest. Eli Lilly stock might ...

April 24 (Reuters) - Eli Lilly's (LLY.N), opens new tab newly launched weight-loss pill had a modest second week, analysts said on Friday, as competition with Danish rival Novo Nordisk (NOVOb.CO), ...

Eli Lilly struck a deal to acquire Kelonia Therapeutics for $3.25 billion, the companies said Monday. The deal price could reach as much as $7 billion if Kelonia reaches certain clinical, regulatory ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...